MA29993B1 - Composition immunogene - Google Patents
Composition immunogeneInfo
- Publication number
- MA29993B1 MA29993B1 MA30522A MA30522A MA29993B1 MA 29993 B1 MA29993 B1 MA 29993B1 MA 30522 A MA30522 A MA 30522A MA 30522 A MA30522 A MA 30522A MA 29993 B1 MA29993 B1 MA 29993B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunogenic composition
- meningitidis
- polysaccharide
- capsular
- serogroups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
L'invention concerne une composition immunogène comprenant des polysaccharides capsulaires N. meningitidis différents d'au moins un des sérogroupes A, C, W135 et Y conjugués avec une protéine porteuse afin d'obtenir un conjugué de polysaccharide capsulaire N. meningitidis, la taille moyenne de chaque polysaccharide N. meningitidis étant supérieure à 50kDa.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0513069.5A GB0513069D0 (en) | 2005-06-27 | 2005-06-27 | Immunogenic composition |
GBGB0513071.1A GB0513071D0 (en) | 2005-06-27 | 2005-06-27 | Immunogenic composition |
GB0515556A GB0515556D0 (en) | 2005-07-28 | 2005-07-28 | Immunogenic composition |
GB0524204A GB0524204D0 (en) | 2005-11-28 | 2005-11-28 | Immunogenic composition |
GB0526040A GB0526040D0 (en) | 2005-12-21 | 2005-12-21 | Immunogenic composition |
GB0526041A GB0526041D0 (en) | 2005-12-21 | 2005-12-21 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29993B1 true MA29993B1 (fr) | 2008-12-01 |
Family
ID=36716943
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30512A MA29603B1 (fr) | 2005-06-27 | 2007-12-26 | Procede de fabrication de vaccins |
MA30511A MA29602B1 (fr) | 2005-06-27 | 2007-12-26 | Composition immunogene |
MA30521A MA29569B1 (fr) | 2005-06-27 | 2007-12-27 | Composition immunogene |
MA30522A MA29993B1 (fr) | 2005-06-27 | 2007-12-27 | Composition immunogene |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30512A MA29603B1 (fr) | 2005-06-27 | 2007-12-26 | Procede de fabrication de vaccins |
MA30511A MA29602B1 (fr) | 2005-06-27 | 2007-12-26 | Composition immunogene |
MA30521A MA29569B1 (fr) | 2005-06-27 | 2007-12-27 | Composition immunogene |
Country Status (37)
Country | Link |
---|---|
US (13) | US8431136B2 (fr) |
EP (11) | EP1896063B2 (fr) |
JP (9) | JP2008543907A (fr) |
KR (7) | KR101532068B1 (fr) |
CN (3) | CN103083657B (fr) |
AP (1) | AP2436A (fr) |
AR (3) | AR056396A1 (fr) |
AT (3) | ATE516816T1 (fr) |
AU (7) | AU2006263963B2 (fr) |
BE (1) | BE2012C042I2 (fr) |
BR (5) | BRPI0612669B8 (fr) |
CA (5) | CA2611964C (fr) |
CY (5) | CY1109996T1 (fr) |
DE (1) | DE602006013313D1 (fr) |
DK (7) | DK1896063T3 (fr) |
EA (4) | EA012506B1 (fr) |
ES (9) | ES2621780T3 (fr) |
FR (1) | FR22C1008I2 (fr) |
HK (4) | HK1114011A1 (fr) |
HR (4) | HRP20100211T1 (fr) |
HU (7) | HUE045482T2 (fr) |
IL (8) | IL187924A (fr) |
LT (1) | LT2351578T (fr) |
LU (1) | LU92085I2 (fr) |
MA (4) | MA29603B1 (fr) |
MX (5) | MX2007016402A (fr) |
MY (3) | MY147783A (fr) |
NL (1) | NL300549I2 (fr) |
NO (4) | NO345422B1 (fr) |
NZ (6) | NZ564605A (fr) |
PE (6) | PE20142165A1 (fr) |
PL (8) | PL2351578T3 (fr) |
PT (8) | PT2283857T (fr) |
SI (8) | SI1896065T2 (fr) |
TW (5) | TWI422386B (fr) |
UA (2) | UA95238C2 (fr) |
WO (6) | WO2007000322A1 (fr) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2375704T5 (es) * | 2000-06-29 | 2016-03-03 | Smithkline Beecham Biologicals S.A. | Composición de vacuna multivalente |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
ATE552844T1 (de) | 2003-01-30 | 2012-04-15 | Novartis Ag | Injizierbarer impfstoff gegen multiple meningokokken-serogruppen |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
SI1896065T2 (sl) † | 2005-06-27 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Postopek za pripravo cepiv |
AU2012261764B2 (en) * | 2005-09-01 | 2016-09-08 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Multiple vaccination including serogroup C meningococcus |
US8007807B2 (en) * | 2005-09-01 | 2011-08-30 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C meningococcus |
MY148141A (en) | 2005-12-22 | 2013-03-15 | Glaxosmithkline Biolog Sa | Vaccine |
ES2383209T3 (es) * | 2006-03-22 | 2012-06-19 | Novartis Ag | Regímenes para la inmunización con conjugados meningococicos |
US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
CA2662051A1 (fr) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccin |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
EP2167120A2 (fr) | 2007-06-26 | 2010-03-31 | GlaxoSmithKline Biologicals S.A. | Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
US20160228500A9 (en) * | 2007-07-23 | 2016-08-11 | Martina Ochs | Immunogenic Polypeptides and Monoclonal Antibodies |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
CN101951949B (zh) | 2007-10-19 | 2013-10-02 | 诺华股份有限公司 | 脑膜炎球菌疫苗制剂 |
WO2010023216A1 (fr) * | 2008-08-28 | 2010-03-04 | Glaxosmithkline Biologicals S.A. | Vaccin |
PT2349520T (pt) | 2008-10-27 | 2016-08-16 | Glaxosmithkline Biologicals Sa | Método de purificação para hidrato de carbono de estreptococos grupo a |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
NZ593674A (en) | 2008-12-17 | 2013-03-28 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
JP5668049B2 (ja) | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
CA2756522C (fr) | 2009-03-24 | 2018-06-26 | Novartis Ag | Proteine de liaison du facteur h meningococcique utilisee comme adjuvant |
JP5593626B2 (ja) * | 2009-03-31 | 2014-09-24 | 凸版印刷株式会社 | 計量スプーン |
EP2419129A2 (fr) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions pour l'immunisation contre staphylococcus aureus |
CA2757620C (fr) * | 2009-04-30 | 2016-04-26 | Coley Pharmaceutical Group, Inc. | Vaccin anti-pneumococcique et ses utilisations |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
TW201544119A (zh) * | 2009-06-22 | 2015-12-01 | Wyeth Llc | 組合物及製備金黃色葡萄球菌血清型5及8莢膜多醣結合物之免疫原性組合物之方法 |
PE20110023A1 (es) | 2009-06-22 | 2011-01-31 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus |
JP5988492B2 (ja) | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Tlr活性モジュレーターを含む免疫原性組成物 |
BR112012008338A2 (pt) | 2009-09-10 | 2019-09-24 | Novartis Ag | combinação de vacinas contra doenças do trato respiratório. |
PT2493498T (pt) | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E.coliキャリアタンパク質に結合体化した多糖免疫原 |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011161653A1 (fr) | 2010-06-25 | 2011-12-29 | Novartis Ag | Associations de protéines de liaison du facteur h méningococcique |
CN103189071A (zh) | 2010-08-23 | 2013-07-03 | 惠氏有限责任公司 | 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂 |
CA2810011A1 (fr) | 2010-09-01 | 2012-03-08 | Novartis Ag | Adsorption d'immunopotentialisateurs en sels metalliques insolubles |
WO2012032489A1 (fr) | 2010-09-10 | 2012-03-15 | Wyeth Llc | Variants non-lipidiques des antigènes orf 2086 de neisseria meningitidis |
EP2613805B1 (fr) | 2010-09-10 | 2019-10-23 | GlaxoSmithKline Biologicals SA | MENINGOCOQUE SUREXPRIMANT NADA ET/OU NHBA ET DES 
VESICULES DE MEMBRANE EXTERNE DÉRIVÉS DE CELLE-CI |
WO2012072769A1 (fr) | 2010-12-01 | 2012-06-07 | Novartis Ag | Epitopes rrgb de pneumocoque et combinaisons de variantes |
TR201811280T4 (tr) | 2011-03-02 | 2018-08-27 | Glaxosmithkline Biologicals Sa | Düşük antijen ve/ veya adjuvan dozları olan karma aşılar. |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
AU2012335208B2 (en) | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
JP2013112653A (ja) * | 2011-11-30 | 2013-06-10 | Jnc Corp | 新規重合体およびその製造方法 |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
WO2013098589A1 (fr) | 2011-12-29 | 2013-07-04 | Novartis Ag | Combinaisons avec adjuvant de protéines méningococciques liant le facteur h |
SG11201404447WA (en) * | 2012-01-30 | 2014-08-28 | Serum Inst India Ltd | Immunogenic composition |
JP5957541B2 (ja) | 2012-02-02 | 2016-07-27 | ノバルティス アーゲー | 髄膜炎菌における増加したタンパク質発現のためのプロモータ |
CN102569723A (zh) * | 2012-02-13 | 2012-07-11 | 华为技术有限公司 | 锂离子电池正极材料及其制备方法、正极及锂离子电池 |
CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
WO2013132043A1 (fr) | 2012-03-08 | 2013-09-12 | Novartis Ag | Vaccins combinés comprenant des agonistes du tlr4 |
US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
AU2013229063B2 (en) | 2012-03-09 | 2016-10-06 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン |
ITMI20121597A1 (it) * | 2012-09-25 | 2014-03-26 | Beta Pharma S A | Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico |
EA201590427A1 (ru) | 2012-10-02 | 2015-09-30 | Глаксосмитклайн Байолоджикалс С.А. | Нелинейные сахаридные конъюгаты |
AU2013351182C1 (en) | 2012-11-30 | 2018-11-08 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
JP2016502994A (ja) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ジフテリア及び/又は破傷風から防御するためのコンジュゲート |
ES2670863T3 (es) | 2013-02-01 | 2018-06-01 | Glaxosmithkline Biologicals Sa | Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll |
CA2903716C (fr) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Polypeptides immunogenes de fusion |
PL2976101T3 (pl) | 2013-03-18 | 2021-03-08 | Glaxosmithkline Biologicals S.A. | Sposób leczenia |
KR102199096B1 (ko) | 2013-09-08 | 2021-01-06 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
IN2014DE02450A (fr) | 2013-09-25 | 2015-06-26 | Suzuki Motor Corp | |
RU2535122C1 (ru) * | 2013-11-06 | 2014-12-10 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения холерогена-анатоксина |
BR112016015525A2 (pt) * | 2014-01-21 | 2017-10-24 | Pfizer | composições imunogênicas compreendendo antígenos sacarídeos capsulares conjugados e uso |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP2921856B1 (fr) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | Analyse quantitative pour de la 4-pyrrolidinopyridine (4-ppy) dans des vaccins conjugués polyssacharide-protéine |
EP3131576B1 (fr) | 2014-04-17 | 2021-06-30 | Medizinische Hochschule Hannover | Moyens et méthodes de production de polysaccharides capsulaires de neisseria meningitidis de faible dispersité |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
IL303998A (en) * | 2015-07-21 | 2023-08-01 | Pfizer | Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses |
US20170333546A1 (en) * | 2015-12-08 | 2017-11-23 | Jl Medical Corporation | Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein |
RU2758090C2 (ru) * | 2016-03-15 | 2021-10-26 | Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. | Новые конъюгаты полисахарида с белком и способ их получения |
EP4309670A2 (fr) * | 2016-09-02 | 2024-01-24 | Sanofi Pasteur, Inc. | Vaccin contre neisseria meningitidis |
CA3035320A1 (fr) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccins contre neisseria gonorrhoeae |
EP3436054B2 (fr) | 2016-09-13 | 2022-07-27 | Allergan, Inc. | Compositions de toxines clostridiales non protéiques |
US11027005B2 (en) * | 2016-10-20 | 2021-06-08 | Km Biologics Co., Ltd. | Method for producing Hib conjugate vaccine using PRP with lowered molecular weight |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
AU2018328038B2 (en) | 2017-09-07 | 2024-03-07 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
WO2019145981A1 (fr) * | 2018-01-29 | 2019-08-01 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Nouvelle composition de vaccin méningococcique et procédé correspondant |
WO2019198096A1 (fr) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Composition de vaccin méningococcique tétravalente et son procédé de préparation |
JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
MX2022006054A (es) | 2019-11-22 | 2022-06-24 | Glaxosmithkline Biologicals Sa | Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos. |
BR112023009109A2 (pt) | 2020-11-13 | 2024-02-06 | Glaxosmithkline Biologicals Sa | Carreadores de proteína bacteriana e métodos de conjugação |
RU2770877C1 (ru) * | 2021-04-08 | 2022-04-22 | Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" | Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB513069A (en) | 1937-04-24 | 1939-10-03 | Linde Air Prod Co | Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas |
GB505518A (en) † | 1938-02-03 | 1939-05-12 | Daniel Morgan Skeins | Improvements in or relating to envelopes |
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4123520A (en) * | 1977-08-01 | 1978-10-31 | Merck & Co., Inc. | Method for preparing high molecular weight meningococcal Group C vaccine |
DE2748132A1 (de) * | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
US4235994A (en) * | 1978-06-26 | 1980-11-25 | Merck & Co., Inc. | High molecular weight meningococcal group C vaccine and method for preparation thereof |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
EP0027888B1 (fr) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Interrupteur à semiconducteur |
DE3040825A1 (de) * | 1980-10-30 | 1982-09-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neues tridekapeptid, verfahren zu seiner herstellung und verwendung |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
NL8500370A (nl) * | 1984-02-22 | 1985-09-16 | Sandoz Ag | Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten. |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
DE3526940A1 (de) | 1985-07-27 | 1987-02-12 | Siegfried Fricker | Anker zum einbetonieren in schwere lasten |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
US4727136A (en) * | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
US5180815A (en) * | 1988-04-13 | 1993-01-19 | Fuji Photo Film Co., Ltd. | Modified protein for carrying hapten |
WO1989011813A1 (fr) | 1988-05-31 | 1989-12-14 | KÖNIG-HAUG, Beatrice | Systeme de rayonnage |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
ES2071288T3 (es) | 1989-12-14 | 1995-06-16 | Ca Nat Research Council | Vacuna mejorada de conjugado de polisacarido de meningococos. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0471177B1 (fr) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Hemagglutinine filamenteuse de Bordetella pertussis à titre de molécules porteuses pour vaccins conjugués |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059692C (fr) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Vaccin conjugue de polysaccharide contre les pneumocoques |
CA2059693C (fr) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Antigenes polysaccharides de streptococcus pneumoniae |
GB2264352A (en) | 1992-01-31 | 1993-08-25 | Richards Eng Ltd | Incineration apparatus |
ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
ES2130265T3 (es) | 1992-05-06 | 1999-07-01 | Harvard College | Region de union al receptor de la toxina difterica. |
EP0835663B1 (fr) | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Vaccins combinés contenant des antigènes de surface du virus de l'Hépatite B et d'autres antigènes |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
ES2126616T3 (es) | 1992-10-27 | 1999-04-01 | American Cyanamid Co | Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna. |
AU5951894A (en) | 1992-12-14 | 1994-07-04 | Western Atlas International, Inc. | Removable piston bore liner for hydraulically actuated seismic vibrator |
US5849301A (en) | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
KR100376361B1 (ko) | 1993-09-22 | 2003-07-18 | 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 | 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법 |
DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
GB9422096D0 (en) | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
WO1996029094A1 (fr) | 1995-03-22 | 1996-09-26 | Andrew Lees | Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation |
DK1090642T3 (da) | 1995-06-07 | 2008-09-22 | Glaxosmithkline Biolog Sa | Vacciner omfattende et polysaccharidantigen-bæreprotein-konjugat og frit bæreprotein |
PT1082965E (pt) | 1995-06-23 | 2009-07-01 | Glaxosmithkline Biolog Sa | Uma vacina com composição que inclui como antigénio um polissacárido conjugado, adsorvido em fosfato de alumínio |
SE9601158D0 (sv) | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
CN1174381C (zh) | 1996-10-23 | 2004-11-03 | 松下电器产业株式会社 | 光盘 |
DE69739981D1 (de) | 1996-10-31 | 2010-10-14 | Human Genome Sciences Inc | Streptococcus pneumoniae-Antigene und Impfstoffe |
WO1998026799A1 (fr) | 1996-12-18 | 1998-06-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Vaccin conjugue contre la salmonella paratyphi a |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
AU4707097A (en) | 1997-09-15 | 1999-04-05 | Pasteur Merieux Serums Et Vaccins | Multivalent vaccines |
WO1999013905A1 (fr) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Mutants de poche de fixation de recepteur d'hemagglutinine de virus de grippe a |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
CA2264970A1 (fr) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Conjugues antigeniques de lipolysaccharides de bacteries gram-negatives |
GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
JP2002513028A (ja) * | 1998-04-28 | 2002-05-08 | ガレニカ ファーマシューティカルズ, インコーポレイテッド | ポリサッカリド抗原結合体 |
DE69941574D1 (de) * | 1998-08-19 | 2009-12-03 | Baxter Healthcare Sa | Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid |
WO2000033882A1 (fr) † | 1998-12-04 | 2000-06-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Conjugue vaccinal vi-repa pour l'immunisation contre la salmonella typhi |
ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
CA2689696C (fr) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions a macromolecules et microparticules adsorbees |
JP2002540074A (ja) | 1999-03-19 | 2002-11-26 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2000061761A2 (fr) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides |
JP4660043B2 (ja) | 1999-06-25 | 2011-03-30 | ワイス・ホールディングズ・コーポレイション | グラム陰性細菌のペプチドグリカン結合リポタンパク質の脂質化された形態の製造 |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
JP4948731B2 (ja) | 1999-12-02 | 2012-06-06 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 凍結乾燥の際に生物学的分子を安定化するための組成物および方法 |
FR2806304B1 (fr) * | 2000-03-17 | 2002-05-10 | Aventis Pasteur | Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
ES2375704T5 (es) * | 2000-06-29 | 2016-03-03 | Smithkline Beecham Biologicals S.A. | Composición de vacuna multivalente |
AU2001280883A1 (en) * | 2000-07-27 | 2002-02-13 | The Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
GB0103170D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
KR100947751B1 (ko) | 2001-01-23 | 2010-03-18 | 아벤티스 파스퇴르 | 다가 수막구균 폴리사카라이드-단백질 접합체 백신 |
GB0107658D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
US6615062B2 (en) | 2001-05-31 | 2003-09-02 | Infraredx, Inc. | Referencing optical catheters |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
KR100981471B1 (ko) | 2002-03-15 | 2010-09-10 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의p4 변형 단백질 |
PT1490409E (pt) * | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CN1816350B (zh) | 2002-05-14 | 2010-11-10 | 莱顿大学 | 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗 |
MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
WO2004011027A1 (fr) | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Vaccins multivalents chimeres a conjugue polysaccharidique |
GB0220199D0 (en) | 2002-08-30 | 2002-10-09 | Univ Utrecht | Mutant protein and refolding method |
NZ574530A (en) | 2002-08-02 | 2010-12-24 | Glaxosmithkline Biolog Sa | Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
EP2351579B1 (fr) * | 2002-10-11 | 2016-09-21 | Novartis Vaccines and Diagnostics S.r.l. | Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes |
CN1401328A (zh) | 2002-10-18 | 2003-03-12 | 北京绿竹生物技术有限责任公司 | 流行性脑脊髓膜炎多糖-蛋白结合疫苗 |
SI1556477T1 (sl) * | 2002-11-01 | 2017-12-29 | Glaxosmithkline Biologicals S.A. | Sušilni postopek |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CN1168501C (zh) | 2002-12-27 | 2004-09-29 | 北京绿竹生物技术有限责任公司 | 一种多糖-蛋白结合疫苗 |
ATE552844T1 (de) * | 2003-01-30 | 2012-04-15 | Novartis Ag | Injizierbarer impfstoff gegen multiple meningokokken-serogruppen |
DE602004010376T2 (de) * | 2003-03-13 | 2008-10-23 | Glaxosmithkline Biologicals S.A. | Verfahren zur reinigung von bakteriellem cytolysin |
EP1603950A2 (fr) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene |
US20050002957A1 (en) * | 2003-05-07 | 2005-01-06 | Ryall Robert P. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
MXPA05014171A (es) | 2003-06-23 | 2007-02-21 | Sanofi Pasteur Inc | Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c. |
KR101034055B1 (ko) | 2003-07-18 | 2011-05-12 | 엘지이노텍 주식회사 | 발광 다이오드 및 그 제조방법 |
EP2366404B1 (fr) * | 2003-08-06 | 2014-11-19 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Vaccins de conjugué de protéine de polysaccharide |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
EP1656687A2 (fr) * | 2003-08-21 | 2006-05-17 | Applera Corporation | Reduction d'une interaction due a la matrice pour analyse par spectrometrie de masse maldi |
BR122017002991B1 (pt) * | 2003-10-02 | 2023-01-10 | Novartis Vaccines And Diagnostics S.R.L. | Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos |
AU2004277342B2 (en) * | 2003-10-02 | 2010-12-16 | Glaxosmithkline Biologicals S.A. | Pertussis antigens and use thereof in vaccination |
EP1706481A2 (fr) * | 2003-12-23 | 2006-10-04 | GlaxoSmithKline Biologicals S.A. | Vaccin |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
WO2005105140A2 (fr) * | 2004-04-30 | 2005-11-10 | Chiron Srl | Integration d'une vaccination conjuguee antimeningococcique |
GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
JP2008513409A (ja) * | 2004-09-22 | 2008-05-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
US20060121055A1 (en) * | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
DK1858920T3 (en) * | 2005-02-18 | 2016-02-29 | Glaxosmithkline Biolog Sa | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US20070184072A1 (en) * | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EP2425855A1 (fr) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Composition conjuguée polysaccharide-protéine pneumococcique polyvalente |
CN101282984B (zh) | 2005-05-06 | 2013-05-08 | 诺华疫苗与诊断股份有限公司 | A型脑膜炎疫苗的免疫原 |
SI1896065T2 (sl) * | 2005-06-27 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Postopek za pripravo cepiv |
CN1709505B (zh) | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
US8007807B2 (en) | 2005-09-01 | 2011-08-30 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C meningococcus |
EP2208999B1 (fr) * | 2005-09-05 | 2014-08-27 | GlaxoSmithKline Biologicals SA | Essai d'activité bactéricide sérique pour des antisérums spécifiques de n. méningitidis |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
MY148141A (en) * | 2005-12-22 | 2013-03-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
BRPI0620418A2 (pt) * | 2005-12-23 | 2011-11-08 | Glaxosmithkline Biolog Sa | método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit |
KR101947794B1 (ko) * | 2006-03-17 | 2019-02-13 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 복합 다가 면역원성 콘쥬게이트의 제조 방법 |
AR060187A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
EP3141261A1 (fr) * | 2006-03-30 | 2017-03-15 | GlaxoSmithKline Biologicals S.A. | Composition immunogène |
MX2008016280A (es) * | 2006-06-29 | 2009-03-26 | Novartis Ag | Polipeptidos a partir de neisseria meningitidis. |
US7491517B2 (en) | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
SG173997A1 (en) | 2006-07-21 | 2011-09-29 | Univ California | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
CA2662051A1 (fr) * | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccin |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
JP4858611B2 (ja) * | 2007-03-14 | 2012-01-18 | コニカミノルタビジネステクノロジーズ株式会社 | 情報埋め込み方法、そのプログラムおよび情報埋め込み装置 |
UY31064A1 (es) * | 2007-05-02 | 2009-01-05 | Glaxosmithkline Biolog Sa | Vacuna |
IN2009KN04098A (fr) * | 2007-06-04 | 2015-08-28 | Novartis Ag | |
EP2167120A2 (fr) | 2007-06-26 | 2010-03-31 | GlaxoSmithKline Biologicals S.A. | Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
WO2010023216A1 (fr) | 2008-08-28 | 2010-03-04 | Glaxosmithkline Biologicals S.A. | Vaccin |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
US8259461B2 (en) * | 2008-11-25 | 2012-09-04 | Micron Technology, Inc. | Apparatus for bypassing faulty connections |
ES2812523T3 (es) * | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8 |
TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
CA2792691A1 (fr) * | 2010-03-11 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Composition immunogene ou vaccin contre une bacterie gram negative, par exemple, infection ou maladie neisserial |
WO2011155196A1 (fr) * | 2010-06-11 | 2011-12-15 | パナソニック株式会社 | Système d'évaluation d'audition d'un son de conversation, son procédé et son programme |
AU2012335208B2 (en) * | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
SG11201404447WA (en) * | 2012-01-30 | 2014-08-28 | Serum Inst India Ltd | Immunogenic composition |
CA2874210A1 (fr) * | 2012-05-22 | 2013-11-28 | Novartis Ag | Conjugue de serogroupe x de meningocoque |
WO2014001328A1 (fr) | 2012-06-25 | 2014-01-03 | Nadiro A/S | Unité de déploiement de canot de sauvetage |
CA2893435A1 (fr) * | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
GB201310008D0 (en) * | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
EP3177324A1 (fr) * | 2014-08-05 | 2017-06-14 | GlaxoSmithKline Biologicals S.A. | Molécule porteuse pour des antigènes |
TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518684D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
EP4309670A2 (fr) * | 2016-09-02 | 2024-01-24 | Sanofi Pasteur, Inc. | Vaccin contre neisseria meningitidis |
US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
US10183070B2 (en) * | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN111032078A (zh) * | 2017-07-18 | 2020-04-17 | 血清研究所印度私人有限公司 | 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法 |
-
2006
- 2006-06-23 SI SI200631109T patent/SI1896065T2/sl unknown
- 2006-06-23 US US11/917,569 patent/US8431136B2/en active Active
- 2006-06-23 EP EP06754599.6A patent/EP1896063B2/fr active Active
- 2006-06-23 SI SI200632346T patent/SI1896061T1/sl unknown
- 2006-06-23 SI SI200632159A patent/SI2351578T1/sl unknown
- 2006-06-23 NZ NZ564605A patent/NZ564605A/en unknown
- 2006-06-23 PL PL10179820T patent/PL2351578T3/pl unknown
- 2006-06-23 ES ES10179820.5T patent/ES2621780T3/es active Active
- 2006-06-23 BR BRPI0612669A patent/BRPI0612669B8/pt active IP Right Grant
- 2006-06-23 BR BRPI0612670A patent/BRPI0612670B8/pt active IP Right Grant
- 2006-06-23 ES ES06762248T patent/ES2901378T3/es active Active
- 2006-06-23 EP EP06762248.0A patent/EP1896066B8/fr active Active
- 2006-06-23 US US11/917,580 patent/US8329184B2/en active Active
- 2006-06-23 PE PE2014001334A patent/PE20142165A1/es active IP Right Grant
- 2006-06-23 US US11/917,610 patent/US9789179B2/en active Active
- 2006-06-23 PL PL06754599T patent/PL1896063T3/pl unknown
- 2006-06-23 EP EP10158046.2A patent/EP2201961B1/fr active Active
- 2006-06-23 PT PT101778322T patent/PT2283857T/pt unknown
- 2006-06-23 AU AU2006263963A patent/AU2006263963B2/en active Active
- 2006-06-23 EP EP06754611.9A patent/EP1896065B2/fr active Active
- 2006-06-23 ES ES06754599.6T patent/ES2377075T5/es active Active
- 2006-06-23 US US11/917,709 patent/US9931397B2/en active Active
- 2006-06-23 EP EP10177832.2A patent/EP2283857B1/fr active Active
- 2006-06-23 KR KR1020137018446A patent/KR101532068B1/ko active IP Right Grant
- 2006-06-23 LT LTEP10179820.5T patent/LT2351578T/lt unknown
- 2006-06-23 KR KR1020087002312A patent/KR101408113B1/ko active IP Right Grant
- 2006-06-23 AU AU2006263936A patent/AU2006263936B2/en active Active
- 2006-06-23 PE PE2006000720A patent/PE20070499A1/es active IP Right Grant
- 2006-06-23 PE PE2010000450A patent/PE20110072A1/es not_active Application Discontinuation
- 2006-06-23 NZ NZ564607A patent/NZ564607A/en unknown
- 2006-06-23 UA UAA200714086A patent/UA95238C2/uk unknown
- 2006-06-23 EA EA200702576A patent/EA012506B1/ru not_active IP Right Cessation
- 2006-06-23 PE PE2006000718A patent/PE20070123A1/es not_active Application Discontinuation
- 2006-06-23 SI SI200630681T patent/SI1896062T1/sl unknown
- 2006-06-23 CA CA2611964A patent/CA2611964C/fr active Active
- 2006-06-23 HU HUE06754582A patent/HUE045482T2/hu unknown
- 2006-06-23 KR KR1020137028209A patent/KR20130122810A/ko not_active Application Discontinuation
- 2006-06-23 DK DK06754599.6T patent/DK1896063T3/da active
- 2006-06-23 EP EP06754610A patent/EP1896064A2/fr not_active Ceased
- 2006-06-23 HU HUE10179820A patent/HUE031380T2/en unknown
- 2006-06-23 PL PL06754582T patent/PL1896061T3/pl unknown
- 2006-06-23 DK DK06754596.2T patent/DK1896062T3/da active
- 2006-06-23 WO PCT/EP2006/006210 patent/WO2007000322A1/fr not_active Application Discontinuation
- 2006-06-23 AU AU2006263965A patent/AU2006263965B2/en active Active
- 2006-06-23 SI SI200631247T patent/SI1896063T1/sl unknown
- 2006-06-23 EA EA200702577A patent/EA013374B1/ru not_active IP Right Cessation
- 2006-06-23 DK DK14198052.4T patent/DK2878307T3/da active
- 2006-06-23 PT PT101798205T patent/PT2351578T/pt unknown
- 2006-06-23 PL PL10177832T patent/PL2283857T3/pl unknown
- 2006-06-23 AP AP2007004274A patent/AP2436A/xx active
- 2006-06-23 NZ NZ590204A patent/NZ590204A/en unknown
- 2006-06-23 US US11/917,702 patent/US9486515B2/en active Active
- 2006-06-23 DK DK06754582.2T patent/DK1896061T3/da active
- 2006-06-23 SI SI200632352T patent/SI2878307T1/sl unknown
- 2006-06-23 EP EP06754596A patent/EP1896062B1/fr not_active Revoked
- 2006-06-23 CN CN201310023297.9A patent/CN103083657B/zh active Active
- 2006-06-23 PT PT151893971T patent/PT3009146T/pt unknown
- 2006-06-23 PL PL06754596T patent/PL1896062T3/pl unknown
- 2006-06-23 ES ES06754596T patent/ES2340711T3/es active Active
- 2006-06-23 CA CA2612957A patent/CA2612957C/fr active Active
- 2006-06-23 WO PCT/EP2006/006220 patent/WO2007000327A1/fr active Application Filing
- 2006-06-23 AR ARP060102723A patent/AR056396A1/es not_active Application Discontinuation
- 2006-06-23 BR BRPI0612656-1A patent/BRPI0612656B1/pt active IP Right Grant
- 2006-06-23 NZ NZ564371A patent/NZ564371A/en not_active IP Right Cessation
- 2006-06-23 BR BRPI0612654A patent/BRPI0612654B8/pt active IP Right Grant
- 2006-06-23 ES ES14198052T patent/ES2747025T3/es active Active
- 2006-06-23 PT PT06754596T patent/PT1896062E/pt unknown
- 2006-06-23 PT PT06754599T patent/PT1896063E/pt unknown
- 2006-06-23 PL PL06754611T patent/PL1896065T5/pl unknown
- 2006-06-23 AT AT06754611T patent/ATE516816T1/de active
- 2006-06-23 AR ARP060102724A patent/AR056397A1/es not_active Application Discontinuation
- 2006-06-23 WO PCT/EP2006/006188 patent/WO2007000314A2/fr active Application Filing
- 2006-06-23 PL PL14198052T patent/PL2878307T3/pl unknown
- 2006-06-23 PL PL15189397T patent/PL3009146T3/pl unknown
- 2006-06-23 EP EP10179820.5A patent/EP2351578B1/fr active Active
- 2006-06-23 DE DE602006013313T patent/DE602006013313D1/de active Active
- 2006-06-23 CN CN2011101438611A patent/CN102218138A/zh active Pending
- 2006-06-23 CN CN201210028358.6A patent/CN102526723B/zh active Active
- 2006-06-23 MX MX2007016402A patent/MX2007016402A/es active IP Right Grant
- 2006-06-23 JP JP2008517440A patent/JP2008543907A/ja active Pending
- 2006-06-23 WO PCT/EP2006/006269 patent/WO2007000342A2/fr active Application Filing
- 2006-06-23 PE PE2006000719A patent/PE20070163A1/es active IP Right Grant
- 2006-06-23 PE PE2010000444A patent/PE20110096A1/es active IP Right Grant
- 2006-06-23 KR KR1020087002217A patent/KR101351870B1/ko active IP Right Grant
- 2006-06-23 CA CA2612963A patent/CA2612963C/fr active Active
- 2006-06-23 EP EP15189397.1A patent/EP3009146B1/fr active Active
- 2006-06-23 JP JP2008517442A patent/JP5731737B2/ja active Active
- 2006-06-23 HU HUE14198052A patent/HUE046905T2/hu unknown
- 2006-06-23 MX MX2007016405A patent/MX2007016405A/es active IP Right Grant
- 2006-06-23 CA CA2611960A patent/CA2611960C/fr active Active
- 2006-06-23 JP JP2008517441A patent/JP5297800B2/ja active Active
- 2006-06-23 NZ NZ564606A patent/NZ564606A/en unknown
- 2006-06-23 AU AU2006263964A patent/AU2006263964B2/en active Active
- 2006-06-23 BR BRPI0612655-3A patent/BRPI0612655B1/pt active IP Right Grant
- 2006-06-23 AR ARP060102725A patent/AR053935A1/es not_active Application Discontinuation
- 2006-06-23 PT PT141980524T patent/PT2878307T/pt unknown
- 2006-06-23 AT AT06754596T patent/ATE462444T1/de active
- 2006-06-23 MX MX2007016237A patent/MX2007016237A/es active IP Right Grant
- 2006-06-23 MX MX2007016403A patent/MX2007016403A/es active IP Right Grant
- 2006-06-23 EP EP06754582.2A patent/EP1896061B1/fr active Active
- 2006-06-23 EA EA200702574A patent/EA012214B1/ru not_active IP Right Cessation
- 2006-06-23 US US11/917,726 patent/US8398983B2/en active Active
- 2006-06-23 DK DK10179820.5T patent/DK2351578T3/en active
- 2006-06-23 ES ES10177832T patent/ES2750243T3/es active Active
- 2006-06-23 DK DK06754611.9T patent/DK1896065T4/da active
- 2006-06-23 KR KR1020077030683A patent/KR101359953B1/ko active IP Right Grant
- 2006-06-23 ES ES15189397T patent/ES2898451T3/es active Active
- 2006-06-23 PT PT06754611T patent/PT1896065E/pt unknown
- 2006-06-23 KR KR1020077031058A patent/KR101351873B1/ko not_active IP Right Cessation
- 2006-06-23 AU AU2006263944A patent/AU2006263944B2/en active Active
- 2006-06-23 WO PCT/EP2006/006270 patent/WO2007000343A2/fr active Application Filing
- 2006-06-23 DK DK10177832T patent/DK2283857T3/da active
- 2006-06-23 HU HUE15189397A patent/HUE056842T2/hu unknown
- 2006-06-23 SI SI200632356T patent/SI2283857T1/sl unknown
- 2006-06-23 EA EA200702575A patent/EA012528B1/ru not_active IP Right Cessation
- 2006-06-23 PT PT06754582T patent/PT1896061T/pt unknown
- 2006-06-23 WO PCT/EP2006/006268 patent/WO2007000341A2/fr active Application Filing
- 2006-06-23 UA UAA200714084A patent/UA95237C2/uk unknown
- 2006-06-23 AT AT06754599T patent/ATE536884T1/de active
- 2006-06-23 EP EP14198052.4A patent/EP2878307B1/fr active Active
- 2006-06-23 JP JP2008517436A patent/JP5280199B2/ja active Active
- 2006-06-23 SI SI200632415T patent/SI3009146T1/sl unknown
- 2006-06-23 KR KR1020077030681A patent/KR101321056B1/ko active IP Right Grant
- 2006-06-23 HU HUE10177832A patent/HUE047211T2/hu unknown
- 2006-06-23 MX MX2007016236A patent/MX2007016236A/es active IP Right Grant
- 2006-06-23 NZ NZ564370A patent/NZ564370A/en unknown
- 2006-06-23 JP JP2008517437A patent/JP5037503B2/ja active Active
- 2006-06-23 ES ES10158046.2T patent/ES2662651T3/es active Active
- 2006-06-23 ES ES06754582T patent/ES2741529T3/es active Active
- 2006-06-23 NO NO20076343A patent/NO345422B1/no active Protection Beyond IP Right Term
- 2006-06-23 CA CA2612980A patent/CA2612980C/fr active Active
- 2006-06-26 TW TW095122969A patent/TWI422386B/zh active
- 2006-06-26 TW TW095122993A patent/TWI477283B/zh active
- 2006-06-26 TW TW102148542A patent/TWI537001B/zh active
- 2006-06-26 MY MYPI20063024A patent/MY147783A/en unknown
- 2006-06-26 MY MYPI20063025A patent/MY147490A/en unknown
- 2006-06-26 TW TW102118476A patent/TW201336507A/zh unknown
- 2006-06-26 MY MYPI20063023A patent/MY148110A/en unknown
- 2006-06-26 TW TW095122979A patent/TWI407970B/zh active
-
2007
- 2007-12-06 IL IL187924A patent/IL187924A/en active IP Right Grant
- 2007-12-07 NO NO20076302A patent/NO344452B1/no unknown
- 2007-12-11 IL IL188045A patent/IL188045A0/en active IP Right Grant
- 2007-12-11 NO NO20076350A patent/NO342815B1/no unknown
- 2007-12-11 IL IL188046A patent/IL188046A/en active IP Right Grant
- 2007-12-12 IL IL188072A patent/IL188072A/en active IP Right Grant
- 2007-12-12 NO NO20076363A patent/NO345305B1/no unknown
- 2007-12-26 MA MA30512A patent/MA29603B1/fr unknown
- 2007-12-26 MA MA30511A patent/MA29602B1/fr unknown
- 2007-12-27 MA MA30521A patent/MA29569B1/fr unknown
- 2007-12-27 MA MA30522A patent/MA29993B1/fr unknown
-
2008
- 2008-04-10 HK HK08104083.2A patent/HK1114011A1/xx active IP Right Maintenance
- 2008-06-12 HK HK15105322.1A patent/HK1206587A1/xx unknown
- 2008-06-17 HK HK08106654.6A patent/HK1116414A1/xx not_active IP Right Cessation
- 2008-06-17 HK HK08106653.7A patent/HK1116413A1/xx not_active IP Right Cessation
-
2010
- 2010-04-14 HR HR20100211T patent/HRP20100211T1/hr unknown
- 2010-04-30 CY CY20101100387T patent/CY1109996T1/el unknown
- 2010-07-21 AU AU2010203115A patent/AU2010203115C1/en active Active
- 2010-08-18 AU AU2010212417A patent/AU2010212417A1/en not_active Abandoned
-
2011
- 2011-06-22 IL IL213718A patent/IL213718A/en active IP Right Grant
- 2011-06-28 IL IL213795A patent/IL213795A/en active IP Right Grant
- 2011-07-29 HR HRP20110567TT patent/HRP20110567T4/hr unknown
- 2011-08-15 IL IL214657A patent/IL214657A0/en unknown
- 2011-09-15 CY CY20111100883T patent/CY1111827T1/el unknown
-
2012
- 2012-02-01 HR HR20120102T patent/HRP20120102T1/hr unknown
- 2012-02-21 CY CY20121100175T patent/CY1112698T1/el unknown
- 2012-04-27 US US13/457,891 patent/US8846049B2/en active Active
- 2012-10-11 IL IL222346A patent/IL222346A/en active IP Right Grant
- 2012-10-16 CY CY2012027C patent/CY2012027I2/el unknown
- 2012-10-18 BE BE2012C042C patent/BE2012C042I2/fr unknown
- 2012-10-19 NL NL300549C patent/NL300549I2/nl unknown
- 2012-10-19 HU HUS1200023C patent/HUS1200023I1/hu unknown
- 2012-10-19 LU LU92085C patent/LU92085I2/fr unknown
- 2012-11-01 JP JP2012241817A patent/JP5769688B2/ja active Active
-
2013
- 2013-02-27 US US13/778,633 patent/US8883163B2/en active Active
- 2013-03-13 JP JP2013050333A patent/JP5718960B2/ja active Active
- 2013-05-14 JP JP2013102249A patent/JP2013209395A/ja active Pending
-
2014
- 2014-10-28 US US14/525,883 patent/US9358279B2/en active Active
-
2015
- 2015-04-28 JP JP2015091394A patent/JP5965512B2/ja active Active
-
2016
- 2016-09-14 US US15/265,597 patent/US10245317B2/en active Active
-
2017
- 2017-02-21 CY CY20171100234T patent/CY1118646T1/el unknown
- 2017-03-20 HR HRP20170457TT patent/HRP20170457T1/hr unknown
- 2017-08-30 US US15/691,440 patent/US10166287B2/en active Active
-
2018
- 2018-11-02 US US16/179,476 patent/US11241495B2/en active Active
-
2019
- 2019-02-05 US US16/268,287 patent/US20200000911A1/en not_active Abandoned
-
2022
- 2022-01-13 HU HUS2200002C patent/HUS2200002I1/hu unknown
- 2022-02-21 FR FR22C1008C patent/FR22C1008I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29993B1 (fr) | Composition immunogene | |
EA201101164A1 (ru) | Иммуногенная композиция | |
ATE419278T1 (de) | Modifizierte saccharide mit verbesserter stabilität in wasser | |
CY1112763T1 (el) | Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια | |
EP1725872B8 (fr) | Analyse de vaccins saccharidiques sans interference | |
GEP20053691B (en) | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine | |
BRPI0718927A2 (pt) | Método de imunização contra os quatro sorotipos da dengue. | |
MA29459B1 (fr) | Vaccins | |
ATE279897T1 (de) | Massagevorrichtung | |
BRPI0516770A (pt) | vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente | |
BRPI0516372A (pt) | conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina | |
ATE416313T1 (de) | Drehkolbenmaschine | |
UA95075C2 (uk) | Імуногенна композиція | |
ATE432609T1 (de) | Selbstfahrende landmaschine | |
FR3109310B1 (fr) | Compositions capillaires comprenant un polysaccharide modifié et un dérivé de cellulose cationique | |
TH86957A (th) | สารผสมที่กระตุ้นภูมิคุ้มกันได้ | |
TW200806314A (en) | Immunogenic composition | |
TH192725S (th) | บานพับ | |
TR200606837U (tr) | Burçlu, kaynaksız, ayarlı menteşe. | |
黄雅钦 et al. | Antibacterial Activity of Novel Complex of Gelatin Hydrolysate and Cerium | |
Burch | Memo-February 21, 2002 University Senate Minutes | |
EA201990131A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция | |
TH87917A (th) | องค์ประกอบที่กระตุ้นภูมิคุ้มกันได้ |